Open AccessEpigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases
Author(s) -
Severson Tesa M.,
Zhu Yanyun,
De Marzo Angelo M.,
Jones Tracy,
Simons Jonathan W.,
Nelson William G.,
Yegnasubramanian Srinivasan,
Freedman Matthew L.,
Wessels Lodewyk,
Bergman Andries M.,
Haffner Michael C.,
Zwart Wilbert
Publication year - 2021
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12923
Subject(s) - epigenomics , prostate cancer , foxa1 , epigenetics , biology , cancer research , metastasis , chromatin , transcription factor , prostate , cancer , ctcf , androgen receptor , genetics , gene , dna methylation , enhancer , gene expression
The epigenomic regulation of transcriptional programs in metastatic prostate cancer is poorly understood. We studied the epigenomic landscape of prostate cancer drivers using transcriptional profiling and ChIP‐seq in four clonal metastatic tumors derived from a single prostate cancer patient. Our epigenomic analyses focused on androgen receptor (AR), which is a key oncogenic driver in prostate cancer, the AR pioneer factor FOXA1, chromatin insulator CCCTC‐Binding Factor, as well as for modified histones H3K27ac and H3K27me3. The vast majority of AR binding sites were shared among healthy prostate, primary prostate cancer, and metastatic tumor samples, signifying core AR‐driven transcriptional regulation within the prostate cell lineage. Genes associated with core AR‐binding events were significantly enriched for essential genes in prostate cancer cell proliferation. Remarkably, the metastasis‐specific active AR binding sites showed no differential transcriptional output, indicating a robust transcriptional program across metastatic samples. Combined, our data reveal a core transcriptional program in clonal metastatic prostate cancer, despite epigenomic differences in the AR cistrome.